Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Neptune Technologies & Bioressources Inc T.NTB

Sector: Healthcare | Sub-Sector: Biotechnology

Neptune Technologies & Bioressources Inc is a biotechnology company engaged in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids.
Price: $2.32 | Change: +$0.06 | %Change: +2.65%
Volume: 41,082 | Day High/Low: 2.32/2.23 | 52 Week High/Low: 3.15/1.26
View modes: 
3 stars

RE:RE:RE:RE:Why NEPT could shocked the market soon.

maybe he doesn't speak French and can understand Andre. LOL.  What a hire that he cannot understrand something so simple.  rate and reply
2.5 stars

RE:RE:RE:Why NEPT could shocked the market soon.

absolutely agree, he would have made a grand entrance to the investment-community, to present a plan and his vision how to turn this company around. But no, even a presentation to the Roth Conference...read more
0 stars

RE:RE:RE:RE:Why NEPT could shocked the market soon.

That is the way I see. Acasti's SP has to be recovered too. I know that they are trying to reserve the cash that they have, but no plan for the new CEO for such a long time is not good. They might...read more
2.5 stars

RE:RE:Why NEPT could shocked the market soon.

vincent, no offense but NTB is not J&J or PFE or...it is a very small company and given how much time in between hire NR and actual start date he shoulda been becoming very conversant..PS i see he got...read more
0 stars

RE:RE:RE:Why NEPT could shocked the market soon.

gold, isn't APO like 20-30% of the "value" of NTB and i can see APO falling -$0.50 this year, which is a big drag, then beyond that can the new CEO drive profits really fast, i suspect they need sales...read more
2.5 stars

Presentation by the CFO???

- who is the captain of the ship ??? - who is representing the company ??? - whom do the investors want to see and hear ??? We do need a visible leader, who is telling the story to the investment...read more
0 stars

RE:Why NEPT could shocked the market soon.

I still think Jim is getting trained on the Neptune story. Only been on board for a month now. He brings a lot of experience & market expertise to Neptune. Good hire.  rate and reply
0 stars

RE:RE:Why NEPT could shocked the market soon.

I said that I did't put much value on Zacks, but honestly with you, I hope that some pumping works.   Oh man, SP is so depressing for such a long period....  rate and reply
0.5 stars

RE:RE:RE:RE:Acasti Receives Full Data for Phase II TRIFECTA Trial

hmmm... so meet with the FDA around may 31, 2015 and so with signficant confidence i predict any potential next FDA sponsored trial will not dose its first patient until 2016..and "ramping up...read more
0.5 stars

RE:Why NEPT could shocked the market soon.

what a silly pumper post. i thought you were more serious than that...too funny, are you taking over for seanut  rate and reply
0 stars

Why NEPT could shocked the market soon.

I don't put much credit on Zacks, but I hope that this comes true soon too. Andre is going to present at 27th Annual Roth Conference again, not Jim. Too early for Jim? http://finance.yahoo.com/news...read more
3 stars

RE:RE:RE:Acasti Receives Full Data for Phase II TRIFECTA Trial

They are saying much more than I thought they would.   They are obviously ramping up because they will be going ahead and all systems are go......   Seriously what is there not to like? LAVAL...read more
4.5 stars

RE:RE:Acasti Receives Full Data for Phase II TRIFECTA Trial

Moronstar4, the only thing puzzling is you and your half glass empty mentality. How much NKO was produced in the last 3 years? Now you know how much Capre could be produced from the NKO. Read between...read more
2 stars

RE:Acasti Receives Full Data for Phase II TRIFECTA Trial

puzzeling last sentense...."to avoid any delays due to inventory shortages????". What inventory-shortages....not enough material for a trial??? lol  rate and reply
0 stars

ACST up Pre-Market...

Acasti Pharma Inc. (ACST) -NasdaqCM 0.55 Feb 27, 4:00PM EST |Pre-Market : 0.62 0.07 (12.73%) 8:53AM EST  rate and reply
0 stars

Acasti Receives Full Data for Phase II TRIFECTA Trial

http://finance.yahoo.com/news/acasti-receives-full-data-phase-123000813.html  rate and reply
0 stars

RE:RE:RE:Nothing has changed

I think you guys are reading it wrong.  I have never thought that we would hear much at the end of February.  All they said was that they would have the full set of data.  I don't think they are going...read more
0 stars

RE:RE:Nothing has changed

At this point I'd just like the trial results. You have to give CEO more time for other items.  rate and reply
3 stars

RE:Nothing has changed

Absolutely agree, nothing has changed!!!! I am just wondering what do we have an IR for. IR = Investor Relations!!!!! What relations??? Anything to communicate to the Investors??? What is the company...read more
3 stars

Nothing has changed

You said:  RE:Acasti Pharma Gains Ahead Of Expected Phase II Results Obviously there's some confusion as to what is going to be said/done. The market seems to believe that there will be a news...read more